ECSP109967A - Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparación y uso de los mismos como medicamentos - Google Patents

Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparación y uso de los mismos como medicamentos

Info

Publication number
ECSP109967A
ECSP109967A EC2010009967A ECSP109967A ECSP109967A EC SP109967 A ECSP109967 A EC SP109967A EC 2010009967 A EC2010009967 A EC 2010009967A EC SP109967 A ECSP109967 A EC SP109967A EC SP109967 A ECSP109967 A EC SP109967A
Authority
EC
Ecuador
Prior art keywords
alkyl
substituted
tetrahydronaftalenes
medications
procedure
Prior art date
Application number
EC2010009967A
Other languages
English (en)
Inventor
Lothar Schwink
Siegfried Stengelin
Matthias Gossel
Torsten Haack
Petra Lennig
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP109967A publication Critical patent/ECSP109967A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La inLa invención se refiere a tetrahidronaftalenos sustituidos de la fórmula (I) a sales fisiológicamente compatibles, al uso de los mismos, a medicamentos que comprenden al menos un tetrahidronaftaleno sustituido de acuerdo con la invención y al uso de los tetrahidronaftalenos sustituidos de acuerdo con la invención y derivados de los mismos en calidad de antagonistas de MCH, en donde en el caso de que X = O, C(R43)(R43'), B = alquilo (C1-C6), alcoxi (C1-C4)-alquilo (C1-C4), hidroxi-alquilo (C1-C6), un anillo no aromático mono-, bi- o espirocíclico de 3 a 10 miembros que puede incluir de 0 a 3 heteroátomos seleccionados del grupo de oxígeno, nitrógeno y azufre, en que el sistema de anillos puede estar sustituido adicionalmente con uno o más de los siguientes sustituyentes: F, CF3, alquilo (C1-C6), O-alquilo (C1-C8), alcoxi (C1-C4)-alquilo (C1-C4), hidroxi-alquilo (C1 C4), oxo, CO(R64), hidroxilo; en donde en el caso de que X = C(R43)(R43'), L3 = C(R62)(R63)O, y un anillo no aromático mono-, bi- o espirocíclico de 4 a 10 miembros, que incluye de 1 a 3 heteroátomos seleccionados del grupo de oxígeno, nitrógeno y azufre, en que el sistema de anillos puede estar sustituido adicionalmente con uno o más de los siguientes sustituyentes: F, CF3, alquilo (C1-C6), alquilo (C1-C4), alcoxi (C1-C4)-alquilo (C1-C4), hidroxi-alquilo (C1 C4), oxo, CO(R64), hidroxilo.
EC2010009967A 2007-08-15 2010-02-12 Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparación y uso de los mismos como medicamentos ECSP109967A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291010A EP2025674A1 (de) 2007-08-15 2007-08-15 Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ECSP109967A true ECSP109967A (es) 2010-03-31

Family

ID=38823517

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009967A ECSP109967A (es) 2007-08-15 2010-02-12 Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparación y uso de los mismos como medicamentos

Country Status (26)

Country Link
US (2) US8609731B2 (es)
EP (2) EP2025674A1 (es)
JP (1) JP2010535827A (es)
KR (1) KR20100063700A (es)
CN (1) CN101784536A (es)
AR (1) AR068059A1 (es)
AU (1) AU2008286316A1 (es)
BR (1) BRPI0815206A2 (es)
CA (1) CA2695955A1 (es)
CL (1) CL2008002414A1 (es)
CO (1) CO6331303A2 (es)
CR (1) CR11235A (es)
DO (1) DOP2010000059A (es)
EC (1) ECSP109967A (es)
MA (1) MA31611B1 (es)
MX (1) MX2010001503A (es)
NI (1) NI201000024A (es)
PA (1) PA8793401A1 (es)
PE (1) PE20090986A1 (es)
RU (1) RU2010109416A (es)
SV (1) SV2010003480A (es)
TN (1) TN2010000075A1 (es)
TW (1) TW200930711A (es)
UY (1) UY31288A1 (es)
WO (1) WO2009021740A2 (es)
ZA (1) ZA201000520B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009123194A1 (ja) * 2008-04-01 2011-07-28 武田薬品工業株式会社 複素環化合物
JPWO2010087454A1 (ja) 2009-01-30 2012-08-02 武田薬品工業株式会社 キノリン誘導体
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
WO2011083804A1 (ja) * 2010-01-06 2011-07-14 武田薬品工業株式会社 インドール誘導体
EP3436003B1 (en) * 2016-03-29 2023-08-23 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds

Family Cites Families (971)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000003A1 (en) 1982-06-14 1984-01-05 Merrill Edward Wilson Process and apparatus for measuring blood viscosity directly and rapidly
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU756965B2 (en) 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
BR0010126A (pt) 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
SI1194425T1 (sl) 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
RU2002107998A (ru) 1999-09-01 2003-11-10 АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE) Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств
WO2001019831A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
DE60028791T2 (de) 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
DZ3335A1 (fr) 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
JPWO2001085693A1 (ja) 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
ATE293101T1 (de) 2000-06-16 2005-04-15 Smithkline Beecham Plc Piperidine zur verwendung als orexin rezeptor antagonisten
CA2384041A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
JP2004502423A (ja) 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
AU2001278508A1 (en) 2000-07-31 2002-02-13 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
HUP0401073A2 (hu) 2000-12-21 2004-09-28 Aventis Pharma Deutschland Gmbh. Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
ATE284872T1 (de) 2001-03-22 2005-01-15 Solvay Pharm Bv 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
EP1258247A1 (en) 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
WO2003002776A2 (en) 2001-06-28 2003-01-09 Algat Sherutey Gimur Teufati Method of anodizing of magnesium and magnesium alloys and producing conductive layers on an anodized surface
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
ES2278077T3 (es) 2001-08-31 2007-08-01 Sanofi-Aventis Deutschland Gmbh Derivados de diarilcicloalquilo, procedimiento para su preparacion y su uso como activadores de ppar.
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
PL368441A1 (en) 2001-09-21 2005-03-21 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
HUP0402113A3 (en) 2001-09-21 2012-05-29 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
CA2461144A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
GT200200188A (es) 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
HUP0700124A2 (en) 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
BR0214344A (pt) 2001-11-22 2004-09-14 Biovitrum Ab Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
IL160630A0 (en) 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL161154A0 (en) 2001-11-22 2004-08-31 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
US20050124652A1 (en) 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
AU2003248354A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Acc inhibitors
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
WO2003087046A1 (en) * 2002-04-09 2003-10-23 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US7229987B2 (en) 2002-05-13 2007-06-12 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
JPWO2003097064A1 (ja) 2002-05-17 2005-09-15 協和醗酵工業株式会社 糖尿病治療剤
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
DE10226462A1 (de) 2002-06-13 2003-12-24 Aventis Pharma Gmbh Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20040002524A1 (en) 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE50312261D1 (de) 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
BR0312957A (pt) 2002-07-27 2005-06-14 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
DE60322075D1 (de) * 2002-07-30 2008-08-21 Merck & Co Inc Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
EA200500322A1 (ru) 2002-08-07 2005-08-25 Мицубиси Фарма Корпорейшн Соединения дигидропиразолопиридина
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN1678589A (zh) 2002-09-05 2005-10-05 安万特医药股份有限公司 作为药物的新氨基吲唑衍生物与含有它们的药物组合物
CA2498272A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
BR0315166A (pt) 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2006506366A (ja) 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
WO2004037251A1 (en) 2002-10-24 2004-05-06 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004041274A1 (en) 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
EP1562574A1 (en) 2002-11-07 2005-08-17 Astrazeneca AB 2-oxo-ethanesulfonamide derivates
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
GB0227813D0 (en) 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
KR20050088194A (ko) 2002-12-19 2005-09-02 머크 앤드 캄파니 인코포레이티드 치환된 아미드
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
FR2849032B1 (fr) 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
GB0230088D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2003297291A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
RU2005128499A (ru) 2003-02-13 2006-01-27 Санофи-Авентис Дойчланд Гмбх (De) Замещенные у азота производные гексагидропиразино (1,2-а) пиримидин-4, 7-диона, способ их получения и их применение в качестве лекарственного средства
DE502004011328D1 (de) 2003-02-13 2010-08-12 Sanofi Aventis Deutschland Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2004074288A1 (en) 2003-02-19 2004-09-02 F. Hoffmann-La Roche Ag Sulfonamide substituted xanthine derivatives for use as pepck inhibitors
WO2004078716A1 (en) 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
EP1460069A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators
EP1460075A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
JP2006521359A (ja) 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としての二環式ピペリジン誘導体
WO2004085403A1 (en) 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2004092181A1 (en) 2003-04-11 2004-10-28 Smithkline Beecham Corporation Heterocyclic mchr1 antagonists
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
JP2006522745A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換１，２，４−トリアゾールの薬学的使用
JP2006522747A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7049323B2 (en) 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
JP4531696B2 (ja) 2003-04-25 2010-08-25 パナソニック株式会社 マルチメディア情報共有システム
US20070173486A1 (en) 2003-05-01 2007-07-26 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
JP2006525298A (ja) 2003-05-01 2006-11-09 ヴァーナリス リサーチ リミテッド アゼチジンカルボキサミド誘導体及びｃｂ１レセプター媒介障害の治療におけるその使用
MXPA05011472A (es) 2003-05-01 2005-12-12 Vernalis Res Ltd Uso de derivados de azetidincarboxamida en terapia.
BRPI0410289A (pt) 2003-05-07 2006-05-16 Pfizer Prod Inc ligantes do receptor de canabinóides e suas utilizações
AU2004238240A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
US7067529B2 (en) 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
AU2004240885A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
JP2007501861A (ja) 2003-05-23 2007-02-01 カイロン コーポレイション Ｍｃ４−ｒアゴニストとしてのグアニジノ置換キナゾリノン化合物
CA2526712A1 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
WO2004106343A2 (en) 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
AU2004251178A1 (en) 2003-06-13 2005-01-06 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
US20060135523A1 (en) 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0314049D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005000339A2 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
RU2344132C2 (ru) 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
FR2856683A1 (fr) 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
SE0301882D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use I
WO2005000974A2 (en) 2003-06-27 2005-01-06 Day-Glo Color Corp. Water-based spray marking composition
WO2005001921A1 (ja) 2003-06-27 2005-01-06 Nec Corporation 薄膜トランジスタ、薄膜トランジスタ基板、電子機器及び多結晶半導体薄膜の製造方法
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
CN1832957A (zh) 2003-07-09 2006-09-13 福布斯梅迪泰克公司 包含甾醇和/或甾烷醇及胆固醇生物合成抑制剂的新化合物和组合物 ,以及它们在治疗或预防多种疾病和症状中的用途
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
WO2005007111A2 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
FR2857570A1 (fr) 2003-07-18 2005-01-21 Didier Leandri Dispositif de suspension de verres a pied autour d'un seau utilisable pour le rafraichissement des boissons
JP2006528180A (ja) 2003-07-22 2006-12-14 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペリジン誘導体
DE10333935A1 (de) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20050249A1 (es) 2003-07-25 2005-06-01 Aventis Pharma Gmbh Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
DE10334309A1 (de) 2003-07-28 2005-03-03 Aventis Pharma Deutschland Gmbh Substituierte Thiazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005021495A2 (en) 2003-08-25 2005-03-10 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EP1660446A2 (en) 2003-08-28 2006-05-31 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
AU2004273865A1 (en) 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
TWI336697B (en) 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
RU2381233C2 (ru) 2003-09-30 2010-02-10 Ново Нордиск А/С Агонисты рецептора меланокортина
US20060247239A1 (en) 2003-10-01 2006-11-02 Hu Xiufeng E Melanin concentrating hormone antagonists
WO2005033063A2 (en) * 2003-10-01 2005-04-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2005042516A2 (en) 2003-10-22 2005-05-12 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
CA2543943A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
PL1682528T3 (pl) 2003-11-07 2008-01-31 Hoffmann La Roche Pochodne benzo[b][1,4]dioksepiny
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CA2545058A1 (en) 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
KR20050045927A (ko) 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
EP1685102A4 (en) 2003-11-12 2008-08-20 Lg Life Sciences Ltd melanocortin
KR20060105785A (ko) 2003-11-19 2006-10-11 카이론 코포레이션 감소된 생체축적을 갖는 퀴나졸리논 화합물
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
EP1538159A1 (en) 2003-12-05 2005-06-08 Santhera Pharmaceuticals (Schweiz) GmbH Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc VOLUNTARY INHIBITION OF CONSUMPTION OF ETHANOL USING MELANOCORTIN RECEPTOR 4 RECEPTOR AGONISTS
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
AU2004312001B2 (en) 2003-12-19 2009-08-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
PT1697370E (pt) 2003-12-19 2007-05-31 Bristol Myers Squibb Co Heterociclos azabicíclicos como moduladores do receptor de canabinóides
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
PL1697371T3 (pl) 2003-12-19 2007-09-28 Bristol Myers Squibb Co Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
EP1557417B1 (en) 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
WO2005063247A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
CA2550373C (en) 2003-12-23 2012-01-31 Merck & Co., Inc. Anti-hypercholesterolemic compounds
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2005067932A1 (en) 2004-01-06 2005-07-28 Janssen Pharmaceutica, N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
ES2349195T3 (es) 2004-01-28 2010-12-28 F. Hoffmann-La Roche Ag Espiro-benzodioxoles y su uso como antagonistas de cb1.
BRPI0507309A (pt) 2004-01-31 2007-06-26 Sanofi Aventis Deutschland derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
WO2005080361A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
FR2866340B1 (fr) 2004-02-13 2006-11-24 Sanofi Synthelabo Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
EP1718609A1 (en) 2004-02-17 2006-11-08 Laboratorios Del Dr. Esteve, S.A. Substituted azetidine compounds, their preparation and use as medicaments
BRPI0507734A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
AU2005214084B2 (en) 2004-02-19 2010-06-03 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
GB0403780D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents
EP1718617B1 (en) 2004-02-20 2009-08-19 AstraZeneca AB 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
WO2005082893A2 (en) 2004-02-25 2005-09-09 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
AU2005219779B2 (en) 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
WO2005086904A2 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
DK1751131T3 (da) 2004-03-10 2009-03-16 Janssen Pharmaceutica Nv MTP-inhiberende arylpiperidiner eller -piperaziner, der er substitueret med 5-leddede heterocykler
DE102004012068A1 (de) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
US20080255216A1 (en) 2004-03-29 2008-10-16 Aster Susan D Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
US7608627B2 (en) 2004-04-05 2009-10-27 Takeda Pharmaceutical Company Limited 6-azaindole compound
JPWO2005097738A1 (ja) 2004-04-06 2008-02-28 大日本住友製薬株式会社 新規スルホンアミド誘導体
JP2007532511A (ja) 2004-04-09 2007-11-15 スミスクライン ビーチャム コーポレーション 低用量医薬品
WO2005103039A1 (en) 2004-04-15 2005-11-03 Neurocrine Biosciences, Inc. 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
EP1747215A1 (en) 2004-05-12 2007-01-31 Aventis Pharmaceuticals, Inc. Substantially pure 2-{¬2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl|-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US7442693B2 (en) 2004-05-28 2008-10-28 Smithkline Beecham Corporation Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
DE102004026532A1 (de) 2004-05-29 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Oxazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
FR2871463B1 (fr) 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
JPWO2006001318A1 (ja) 2004-06-24 2008-07-31 塩野義製薬株式会社 スルホンアミド化合物
KR20070041452A (ko) 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
CN101001850A (zh) 2004-06-24 2007-07-18 因塞特公司 酰胺基化合物及其作为药物的应用
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
DE102004034697A1 (de) 2004-07-17 2006-02-09 Sanofi-Aventis Deutschland Gmbh Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung
FR2873368B1 (fr) 2004-07-26 2008-01-04 Merck Sante Soc Par Actions Si Derives de guanidine et leurs utilisations en therapeutique
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
BRPI0513864A (pt) 2004-07-28 2008-05-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
FR2873690B1 (fr) 2004-07-29 2006-10-13 Sanofi Synthelabo Derives d'oxopiperidine, leur preparation et leur application en therapeutique
FR2873693B1 (fr) 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
DE102004037554A1 (de) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038270A1 (de) 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038268A1 (de) 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2575736A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
DE102004038269A1 (de) 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Piperidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006016194A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
DE102004039507A1 (de) 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20080261952A1 (en) 2004-08-16 2008-10-23 Jason Bloxham Aryl Urea Derivatives for Treating Obesity
EP1778250A2 (en) 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
NZ553159A (en) 2004-08-30 2010-05-28 Janssen Pharmaceutica Nv N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006029699A1 (en) 2004-09-11 2006-03-23 Sanofi-Aventis Deutschland Gmbh 7-azaindoles and their use as ppar agonists
WO2006058064A2 (en) 2004-11-29 2006-06-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE602005012292D1 (de) 2004-09-29 2009-02-26 Hoffmann La Roche Indozolonderivate als 11b-hsd1-inhibitoren
EP1803729A4 (en) 2004-09-29 2008-10-01 Kissei Pharmaceutical HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
AU2005292134B2 (en) 2004-10-01 2010-12-23 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
CN101076524A (zh) 2004-10-12 2007-11-21 法马科皮亚药物研发公司 作为选择性黑色素浓集激素受体拮抗剂的治疗肥胖和相关病症的双环化合物
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
EP1805180A1 (en) 2004-10-22 2007-07-11 SmithKline Beecham Corporation Xanthine derivatives with hm74a receptor activity
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
PT1807072E (pt) 2004-10-29 2009-02-16 Lilly Co Eli Derivados de cicloalquil lactama como inibidores de 11- beta-hidroxi-esteróide desidrogenase 1
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
JP2006131559A (ja) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
WO2006051662A1 (ja) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
JP2006160733A (ja) 2004-11-15 2006-06-22 Taisho Pharmaceut Co Ltd シアノフルオロピロリジン誘導体を有効成分として含有する医薬
JPWO2006059744A1 (ja) 2004-11-30 2008-06-05 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
DE102004058449A1 (de) 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
EP1824835A1 (en) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
WO2006065826A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
DE102004060542A1 (de) 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
EP1888544A2 (en) 2004-12-17 2008-02-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
JP2008524137A (ja) 2004-12-18 2008-07-10 バイエル・ヘルスケア・アクチェンゲゼルシャフト （５ｓ）−３−［（ｓ）−フルオロ（４−トリフルオロメチルフェニル）メチル−５，６，７，８−テトラヒドロキノリン−５−オール誘導体およびｃｅｔｐ阻害剤としてのそれらの使用
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
JP2008525404A (ja) 2004-12-23 2008-07-17 アストラゼネカ アクチボラグ 治療剤
US20080319019A1 (en) 2004-12-23 2008-12-25 Leifeng Cheng Therapeutic Agents
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
MX2007007553A (es) 2004-12-24 2007-08-15 Prosidion Ltd Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
KR20070090206A (ko) 2004-12-24 2007-09-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 2환식 피롤 유도체
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ555966A (en) 2005-01-05 2011-03-31 Abbott Lab Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
WO2006073167A1 (ja) 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DE102005002130A1 (de) 2005-01-17 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel
US7956061B2 (en) 2005-01-19 2011-06-07 Merck Sharp & Dohme Corp. Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP2008100916A (ja) 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008528700A (ja) 2005-02-03 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
EP1847531A4 (en) 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
DE602006009773D1 (de) 2005-02-11 2009-11-26 Lilly Co Eli Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
EP1848699A1 (en) 2005-02-14 2007-10-31 Smithkline Beecham Corporation Anthranilic acid derivatives as hm74a receptor agonists
GB0503056D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503053D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
ES2358342T3 (es) 2005-02-15 2011-05-09 Kissei Pharmaceutical Co., Ltd. Compuesto 1-sustituido-7-(beta-d-glicopiranosiloxi)(aza)indol y composición farmacéutica comprendiendo el mismo.
RU2007128987A (ru) 2005-02-15 2009-03-27 Ново Нордиск А/С (DK) 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры
FR2882054B1 (fr) 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2882365B1 (fr) 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
ZA200708144B (en) 2005-02-25 2008-11-26 Takeda Pharmaceutical Pyridyl acetic acid compounds
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1861416A1 (en) 2005-03-09 2007-12-05 The Board of Trustees of Leland Stanford Junior University Obestatin and its uses
DE602006003538D1 (de) 2005-03-09 2008-12-18 Hoffmann La Roche Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
DE102005012874A1 (de) 2005-03-19 2006-09-21 Sanofi-Aventis Deutschland Gmbh Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102005012873B4 (de) 2005-03-19 2007-05-03 Sanofi-Aventis Deutschland Gmbh Aminocarbonyl substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
TW200722432A (en) 2005-03-25 2007-06-16 Sankyo Co Thiazole compounds
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
CN101151244B (zh) 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
CN101160125A (zh) 2005-04-13 2008-04-09 默克公司 烟酸受体激动剂、含有这样化合物的组合物和治疗方法
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
DE102005017605B4 (de) 2005-04-16 2007-03-15 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Aminoalkylthio-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
AU2006236226B2 (en) 2005-04-19 2012-07-05 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
WO2006111849A1 (en) 2005-04-20 2006-10-26 Pfizer Products Inc. Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
US20080194494A1 (en) 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
FR2885627B3 (fr) 2005-05-10 2007-06-22 Espace Production Internationa Procede de fabrication de lames de revetement de sol et lames issues de ce procede, feuille decor pour panneaux de revetement de sol
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
AU2006244043A1 (en) 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
PL1881850T3 (pl) 2005-05-13 2011-03-31 Lilly Co Eli Pegylowane związki GLP-1
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
WO2006127530A2 (en) 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20090099355A1 (en) 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
AU2006255944B2 (en) 2005-06-08 2010-03-04 Japan Tobacco Inc. Heterocyclic compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005026808A1 (de) 2005-06-09 2006-12-14 Sanofi-Aventis Deutschland Gmbh Benzooxazol-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005026809A1 (de) 2005-06-09 2006-12-14 Sanofi-Aventis Deutschland Gmbh Benzothiazol-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
CN101198338A (zh) 2005-06-15 2008-06-11 默克公司 抗高胆固醇血化合物
BRPI0611853A2 (pt) 2005-06-16 2010-10-05 Pfizer derivados de n-(piridin-2-il)-sulfonamida
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
US7605289B2 (en) 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
EP1928859A1 (en) 2005-06-17 2008-06-11 Carex SA Pyrazole derivates as cannabinoid receptor modulators
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
ES2353818T3 (es) 2005-06-22 2011-03-07 F. Hoffmann-La Roche Ag (6-fluor-benzo[1,3]dioxolil)-morfolin-4-il-metanonas y su uso como ligandos de cb1.
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
WO2007001939A1 (en) 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
KR100979582B1 (ko) 2005-07-05 2010-09-01 에프. 호프만-라 로슈 아게 피리다진 유도체
US7999114B2 (en) 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
EP1904466A1 (en) 2005-07-08 2008-04-02 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
WO2007007040A1 (en) 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1902052B1 (en) 2005-07-09 2012-11-28 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
MX2008000560A (es) 2005-07-11 2008-03-10 Mitsubishi Tanabe Pharma Corp Un derivado de oxima y sus preparaciones.
WO2007007910A1 (ja) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. ヘテロ環置換ベンズイミダゾール誘導体
JP2007022943A (ja) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd スクアレン合成酵素阻害薬
CA2615938C (en) 2005-07-14 2014-04-29 Novo-Nordisk A/S Urea glucokinase activators
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
EP1757587A1 (en) 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
ES2326952B1 (es) 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida.
US20090203581A1 (en) 2005-07-18 2009-08-13 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
EP1910375B1 (en) 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
ES2325558T3 (es) 2005-07-20 2009-09-08 Eli Lilly And Company Derivados de piridina como inhibidores de dipeptidilpeptidasa.
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
MX2008000885A (es) 2005-07-21 2008-03-18 Hoffmann La Roche Compuestos de pirido[2,3-d]pirimidin-2,4-diamina como inhibidores de la proteina tirosina fosfatasa 1b.
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
WO2007017126A2 (en) 2005-07-29 2007-02-15 Laboratorios Del Dr. Esteve, S.A. POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
JPWO2007013691A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 スピロ環化合物
US7827993B2 (en) 2005-07-29 2010-11-09 Mayo Foundation For Medical Education And Research Skin pressure reduction to prevent decubitus ulcers by partial magnetic levitation
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
ES2326357B1 (es) 2005-07-29 2010-04-21 Laboratorios Del Dr. Esteve, S.A. Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento.
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
ES2267400B1 (es) 2005-08-04 2008-03-01 Universitat De Valencia Composiciones pigmentarias en base acuosa para marcado policromatico de materiales inorganicos con laser.
EP1912968A1 (en) 2005-08-04 2008-04-23 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1915355A1 (en) 2005-08-08 2008-04-30 AstraZeneca AB Therapeutic agents
CN101282954A (zh) 2005-08-08 2008-10-08 阿斯利康(瑞典)有限公司 治疗剂
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
KR20080038396A (ko) 2005-08-10 2008-05-06 스미스클라인 비참 코포레이션 선택적 ｈｍ７４ａ 작동제로서의 크산틴 유도체
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
WO2007020502A2 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
EP1945635B1 (en) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
JP5075125B2 (ja) 2005-08-26 2012-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防用ジペプチジルペプチダーゼｉｖ阻害剤としての縮合アミノピペリジン
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
US20090258862A1 (en) 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
JPWO2007026761A1 (ja) 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007028145A2 (en) 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US20080300251A1 (en) 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
ES2289888B1 (es) 2005-09-08 2008-12-16 Consejo Superior Investig. Cientificas Derivados de pirazolcarboxamida, su procedimiento de obtencion y sus aplicaciones como antagonistas/agonistas inversos del receptor cannabinoide cb1 y opioide mu.
GB2429975A (en) 2005-09-08 2007-03-14 Univ Edinburgh 1,5-substituted-1H-tetrazole 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
MXPA05009633A (es) 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
GB0518819D0 (en) 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
GB0518817D0 (en) 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
CN101263140A (zh) 2005-09-16 2008-09-10 阿斯利康(瑞典)有限公司 作为葡萄糖激酶活化剂的杂双环化合物
BRPI0616245A2 (pt) 2005-09-16 2011-06-14 Arena Pharm Inc modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
JP2009508885A (ja) 2005-09-21 2009-03-05 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2007038138A2 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
AU2005337101A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
ATE458480T1 (de) 2005-09-23 2010-03-15 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid- modulatoren
WO2007038045A1 (en) 2005-09-23 2007-04-05 Janssen Pharmaceutica, N.V. Tetrahydro-indazolyl cannabinoid modulators
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
AU2006299086A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridyl-1, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
JP2009510069A (ja) 2005-09-30 2009-03-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
JP2009513573A (ja) 2005-09-30 2009-04-02 メルク エンド カムパニー インコーポレーテッド コレステリルエステル転送蛋白阻害剤
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
US20070105819A1 (en) 2005-10-17 2007-05-10 Roger Olsson CB-1 modulating compounds and their use
DE102005049954A1 (de) 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2006304434B2 (en) 2005-10-20 2012-04-05 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
DE102005052101A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2627910A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
CN101355938A (zh) 2005-11-01 2009-01-28 高点制药有限责任公司 取代的酰胺的药学应用
KR20080076916A (ko) 2005-11-01 2008-08-20 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
EP1948644A1 (en) 2005-11-03 2008-07-30 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
UA95613C2 (ru) 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
JP5107253B2 (ja) 2005-11-17 2012-12-26 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
CN101312940B (zh) 2005-11-17 2012-11-14 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
WO2007057768A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Sulfonyl derivatives
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP2009515926A (ja) 2005-11-18 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー アザインドール−２−カルボキサミド誘導体
GB0523609D0 (en) 2005-11-19 2005-12-28 Vernalis R&D Ltd Piperazine derivatives
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
CN101312723B (zh) 2005-11-22 2012-01-11 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
CA2630718A1 (en) 2005-11-22 2007-05-31 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU2006342059B2 (en) 2005-11-23 2012-05-10 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007060992A1 (ja) 2005-11-25 2007-05-31 Kaneka Corporation メタボリックシンドロームもしくはインスリン抵抗性症候群の予防または改善剤
AR058199A1 (es) 2005-11-28 2008-01-23 Merck & Co Inc Derivados de 3- alquilazetidina sustituidos con heterociclos
WO2007064272A1 (en) 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
WO2007063928A1 (ja) 2005-11-30 2007-06-07 Toray Industries, Inc. 新規な非環状アミンカルボキシアミド誘導体及びその塩
EP1959951B1 (en) 2005-12-01 2009-12-23 F. Hoffmann-la Roche AG Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
CN1978445B (zh) 2005-12-02 2010-09-01 中国科学院上海药物研究所 一种可用作人源腺苷单核苷酸激活蛋白激酶激活剂的化合物及其制备方法和应用
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
AU2006326540A1 (en) 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
EP1962601B1 (en) 2005-12-14 2014-10-15 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
CA2633243C (en) 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
JP2009519290A (ja) 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｃ］ピリジン誘導体
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
KR20150003157A (ko) 2005-12-19 2015-01-08 트러스티즈 오브 터프츠 칼리지 소프트 단백질분해효소 억제자 및 이의 프로-소프트 폼
CA2633584A1 (en) 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
CA2633181A1 (en) 2005-12-21 2007-06-28 F. Hoffmann-La Roche Ag Salt and polymorph of dpp-iv inhibitor
WO2007075629A2 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
KR20070066988A (ko) 2005-12-22 2007-06-27 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 아미노 피리미딘유도체와 이의 제조방법 및 이를 유효성분으로 함유하는약학 조성물
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma Inc ácidos fenóxi acéticos como ativadores de ppar delta
WO2007071738A1 (en) 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
CN100999517B (zh) 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
AR058985A1 (es) 2006-01-13 2008-03-05 Schering Corp Diaril piperidinas como moduladores de cb1.
CA2635211A1 (en) 2006-01-13 2007-08-02 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP1976840A1 (en) 2006-01-13 2008-10-08 F.Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators
MX2008009354A (es) 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
RU2449999C2 (ru) 2006-01-18 2012-05-10 Эвольва Са Модуляторы ppar
WO2007133820A2 (en) 2006-01-19 2007-11-22 Neurogen Corporation Diaryl triazolones as cb1 antagonists
BRPI0706654A2 (pt) 2006-01-20 2011-04-05 Smithkline Beecham Corp composição farmacêutica, método para tratar condições ou distìrbios em um mamìfero, uso de um composto, e, composto
US20090170847A1 (en) 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
ATE479656T1 (de) 2006-01-23 2010-09-15 Hoffmann La Roche Cyclohexyl-sulfonamid-derivate mit h3- rezeptoraktivität
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
CN101007804B (zh) 2006-01-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 1,3-苯并间二氧杂环戊烯-2,2-二羧酸衍生物、其制备方法和医疗用途
EP1978804B1 (en) 2006-01-25 2014-07-30 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007089512A1 (en) 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
RU2008135126A (ru) 2006-01-30 2010-03-10 Айрм Ллк (Bm) Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar
KR20080086529A (ko) 2006-01-30 2008-09-25 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
PL1979355T3 (pl) 2006-01-30 2011-04-29 Irm Llc Pochodne spiro imidazoli jako modulatory PPAR
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US20070197530A1 (en) 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
EP1816125A1 (en) 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
US7863302B2 (en) 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US7691876B2 (en) 2006-02-07 2010-04-06 Hoffmann-La Roche Inc. Heterobicyclic amide compounds
US7678818B2 (en) 2006-02-07 2010-03-16 Hoffmann-La Roche Inc. Anthranilamide and 2-amino-heteroarene-carboxamide compounds
PA8713501A1 (es) 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
ATE500222T1 (de) 2006-02-07 2011-03-15 Hoffmann La Roche Benzamid- und heteroarenderivate als cetp- inhibitoren
US7572823B2 (en) 2006-02-07 2009-08-11 Hoffmann-La Roche Inc. Heteroaryl carboxamide compounds
US20090076049A1 (en) 2006-02-07 2009-03-19 Astrazeneca Ab Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1
WO2007092364A2 (en) 2006-02-07 2007-08-16 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007094962A2 (en) 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders
CA2642159A1 (en) 2006-02-10 2007-08-16 Gunderboom, Inc. Filter cartridges for fluid intake systems
EP1983972A4 (en) 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2007095513A1 (en) 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
DE102006006648A1 (de) 2006-02-14 2007-08-23 Merck Patent Gmbh Mandelsäurehydrazide
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
US20070219258A1 (en) 2006-02-15 2007-09-20 Keyes Robert F Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
EP1989191B1 (en) 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
AU2007218053B2 (en) 2006-02-15 2010-05-27 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
US8138188B2 (en) 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2007100833A2 (en) 2006-02-24 2007-09-07 Wyeth Gpat4 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase
US20080038278A1 (en) 2006-02-24 2008-02-14 Jingsong Cao GPAT3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8268867B2 (en) 2006-02-27 2012-09-18 Cadila Healthcare Limited 1,3-dioxane carboxylic acids
ATE530066T1 (de) 2006-02-28 2011-11-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
WO2007099385A1 (en) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase iv inhibitor compounds and compositions
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
WO2007100027A1 (ja) 2006-03-02 2007-09-07 Daiichi Sankyo Company, Limited 光学活性なチアゾリジンジオン誘導体
WO2007101270A1 (en) 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
EP1993543A2 (en) 2006-03-03 2008-11-26 Merck & Co., Inc. Novel crystalline forms of antidiabetic compounds
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20080051452A1 (en) 2006-03-06 2008-02-28 Avestha Gengraine Technologies Pvt. Ltd. Hexanoic acid derivatives as dipeptidyl peptidase inhibitors
US20070270492A1 (en) 2006-03-06 2007-11-22 Avestha Gengraine Technologies Pvt. Ltd. Nananoic acid derivatives as dipeptidyl peptidase inhibitors
JP2009132620A (ja) 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
TW200800979A (en) 2006-03-07 2008-01-01 Lundbeck & Co As H Halogenated sulfonamide derivatives
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
ZA200807715B (en) 2006-03-09 2009-11-25 Pharmacopeia Inc 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
AU2007226673A1 (en) 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
ATE494782T1 (de) 2006-03-10 2011-01-15 Neurogen Corp Piperazinyl-oxoalkyl-tetrahydroisochinoline und verwandte analoga
WO2007105650A1 (ja) 2006-03-10 2007-09-20 Ajinomoto Co., Inc. ４－ヒドロキシイソロイシン誘導体および同誘導体の製造方法
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
WO2007106469A2 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
US8486890B2 (en) 2006-03-15 2013-07-16 Novo Nordisk A/S Amylin derivatives
ZA200807451B (en) 2006-03-16 2010-01-27 Astellas Pharma Inc A triazole derivative or salt thereof
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
DE102006012548A1 (de) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
US20100168083A1 (en) 2006-03-21 2010-07-01 Soren Ebdrup Adamantane derivatives for the treatment of the metabolic syndrome
JP5031817B2 (ja) 2006-03-22 2012-09-26 エフ．ホフマン−ラ ロシュ アーゲー １１β−ＨＳＤ１としてのピラゾール
MX2008012185A (es) 2006-03-23 2008-10-02 Inotek Pharmaceuticals Corp Compuestos de purina y metodos de uso de los mismos.
AU2007231594A1 (en) 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
CA2645639A1 (en) 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
FR2898894B1 (fr) 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
FR2898892A1 (fr) 2006-03-24 2007-09-28 Genfit Sa Derives de n-(phenethyl)benzamide substitues,preparation et utilisations
WO2007117381A2 (en) 2006-03-24 2007-10-18 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
JP2007291075A (ja) 2006-03-27 2007-11-08 Sankyo Co Ltd 新規化合物ステレニン及びその製造方法
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2007229637A1 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of G protein related diseases
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
DE102006014685A1 (de) 2006-03-28 2007-10-04 Sanofi-Aventis Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE102006014688A1 (de) 2006-03-28 2007-10-04 Sanofi-Aventis Azolopyridin-3-on-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
AU2007245037A1 (en) 2006-03-29 2007-11-08 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
CN101454327A (zh) 2006-03-30 2009-06-10 Irm责任有限公司 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
EP2004643A1 (en) 2006-03-31 2008-12-24 Novartis AG Organic compounds
US7851654B2 (en) 2006-04-03 2010-12-14 Industry-Academic Cooperation Foundation Gyeongsang National University Chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
WO2007113634A1 (en) 2006-04-03 2007-10-11 Matrix Laboratories Ltd. Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them
CN101050194B (zh) 2006-04-05 2013-08-21 上海恒瑞医药有限公司 双环辛烷类衍生物、其制备方法及其在医药上的用途
WO2007116229A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
BRPI0710669A2 (pt) 2006-04-07 2011-08-16 High Point Pharmaceuticals Llc compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1
EP1842846A1 (en) 2006-04-07 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Phenylpiperidine derivatives as melanocortin-4 receptor modulators
KR20090047391A (ko) 2006-04-07 2009-05-12 데벨로겐 악틴게젤샤프트 약제학적 조성물을 위한 Ｍｎｋ1/Ｍｎｋ2 억제 활성을 갖는티에노피리미딘
US20100029716A1 (en) 2006-04-10 2010-02-04 Concert Pharmaceuticals, Inc. Novel 1,2,3,4- tetrahydroquinoline derivatives
MX2008013137A (es) 2006-04-11 2008-10-21 Novartis Ag Compuestos organicos.
CA2648642A1 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CN101460453B (zh) 2006-04-11 2012-10-03 埃科特莱茵药品有限公司 磺酰胺化合物
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2007116092A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
JP2009533375A (ja) 2006-04-12 2009-09-17 エフ．ホフマン−ラ ロシュ アーゲー ５−アミド−２−カルボキサミドインドール類
CA2649302A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
EP2015769A4 (en) 2006-04-13 2013-12-25 Ipsen Pharma PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDINE 4 AND THEIR ANALOGUES
JP2007284090A (ja) 2006-04-14 2007-11-01 Dic Plastics Inc 蓋体の係止構造および容器
EP2009011A1 (en) 2006-04-14 2008-12-31 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2007119837A1 (ja) 2006-04-14 2007-10-25 Ajinomoto Co., Inc. リパーゼ阻害剤
FR2899899A1 (fr) 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
CN102643248A (zh) 2006-04-18 2012-08-22 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
WO2007122970A1 (ja) 2006-04-20 2007-11-01 Osaka University 核内受容体に結合するリガンド
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
ES2533263T3 (es) 2006-04-21 2015-04-08 Eli Lilly And Company Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
AU2007240458B2 (en) 2006-04-21 2012-03-15 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
GB0607951D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
AU2007240450B2 (en) 2006-04-21 2011-12-22 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2007123949A2 (en) 2006-04-21 2007-11-01 Schering Corporation Cannabinoid receptor modulators
WO2007122634A2 (en) 2006-04-24 2007-11-01 Jubilant Biosys Limited Pyrimidinediones as tyrosine kinase inhibitors
ATE473210T1 (de) 2006-04-24 2010-07-15 Lilly Co Eli Substituierte pyrrolidinone als hemmer von 11- beta-hydroxysteroiddehydrogenase 1
AU2007244971B2 (en) 2006-04-24 2012-01-19 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
UA94741C2 (en) 2006-04-24 2011-06-10 Эли Лилли Энд Компани Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
DE602007004324D1 (en) 2006-04-25 2010-03-04 Lilly Co Eli 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
ES2429570T3 (es) 2006-04-25 2013-11-15 Eli Lilly And Company Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
JP5324427B2 (ja) 2006-04-25 2013-10-23 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
CN101432285A (zh) 2006-04-26 2009-05-13 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
WO2007121687A1 (fr) 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
WO2007122411A1 (en) 2006-04-26 2007-11-01 Astrazeneca Ab Diazepan-1-yl-sulfonyl derivatives for the treatment of metabolic syndrome
US20070254863A1 (en) 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
WO2007126043A1 (ja) 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP1849785A1 (en) 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
WO2007127901A1 (en) 2006-04-28 2007-11-08 Eli Lilly And Company Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US9150507B2 (en) 2006-04-28 2015-10-06 Shionogi & Co., Ltd. Amine derivative having NPY Y5 receptor antagonistic activity
CA2649577A1 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
DE602007010764D1 (en) 2006-04-28 2011-01-05 Transtech Pharma Inc Benzamidglucokinaseaktivatoren
CA2649677A1 (en) 2006-05-01 2007-11-15 Incyte Corporation Tetrasubstituted ureas as modulators of 11-.beta. hydroxyl steroid dehydrogenase type 1
JP2009167104A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
EP1854806A1 (en) 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycosides as pharmaceutically active agents
JP2009167103A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
AU2007258117B2 (en) 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
CA2651385C (en) 2006-05-05 2015-02-03 John F. Mcelroy Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
US8232403B2 (en) 2006-05-10 2012-07-31 Novartis Ag Bicyclic derivatives as CETP inhibitors
US20120088746A1 (en) 2006-05-10 2012-04-12 Pfizer Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
BRPI0711416A2 (pt) 2006-05-11 2011-11-01 Sanofi Aventis ácidos carboxìlicos substituìdos com 4,5-difenil pirimidinila, processo para a produção e uso dos mesmos como medicamentos
WO2007134149A2 (en) 2006-05-11 2007-11-22 Janssen Pharmaceutica N.V. 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2009536953A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての１，２，３，４−テトラヒドロ−キノリン誘導体
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101443324A (zh) 2006-05-11 2009-05-27 诺瓦提斯公司 作为cetp抑制剂的苄胺衍生物
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7851468B2 (en) 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
TW200812588A (en) 2006-05-15 2008-03-16 Neurogen Corp CRF1 receptor ligands comprising heteroaryl fused bicycles
PE20080069A1 (es) 2006-05-15 2008-02-22 Merck & Co Inc Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
CA2651777A1 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. Pro-drugs of tertiary alcohols
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP5167250B2 (ja) 2006-05-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
CA2652375A1 (en) 2006-05-17 2007-11-29 Incyte Corporation Heterocyclic inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type i and methods of using the same
EP2024334A4 (en) 2006-05-18 2009-09-30 Merck & Co Inc SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS
WO2007134958A1 (en) 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
EP2019673A4 (en) 2006-05-18 2010-06-16 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
MX2008014512A (es) 2006-05-19 2008-11-27 Taisho Pharma Co Ltd Compuesto de c-fenil glucitol para el tratamiento de diabetes.
AU2007254232A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EP2038256A1 (en) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
WO2007134986A1 (en) 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
WO2007135427A1 (en) 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
CL2007001451A1 (es) 2006-05-24 2008-01-11 Eli Lilly And Company Soc Organizada Bajo Las Leyes Del Estado De Indiana Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
JP5119241B2 (ja) 2006-05-24 2013-01-16 イーライ リリー アンド カンパニー Ｆｘｒアゴニスト
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
MY147954A (en) 2006-05-26 2013-02-15 Nestec Sa Methods of use and nutritional compositions of touchi extract
WO2007140005A2 (en) 2006-05-26 2007-12-06 Janssen Pharmaceutica N.V. Oxazolyl piperidine modulators of fatty acid amide hydrolase
JP2009538323A (ja) 2006-05-26 2009-11-05 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および／または１１β−ヒドロキシラーゼ阻害剤
TW200806625A (en) 2006-05-26 2008-02-01 Astrazeneca Ab Therapeutic compounds
ATE538116T1 (de) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
US7902184B2 (en) 2006-05-30 2011-03-08 Hoffmann-La Roche Inc. Piperazinyl pyrimidine derivatives
CN101495456B (zh) 2006-05-30 2014-03-19 詹森药业有限公司 作为组胺h3受体的调节剂的取代的吡啶基酰胺化合物
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2024349B1 (en) 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2007140385A2 (en) 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2007138050A1 (en) 2006-05-31 2007-12-06 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
EP2032548A1 (en) 2006-06-01 2009-03-11 F.Hoffmann-La Roche Ag Thiazole derivatives
AU2007254827A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
JP2009190971A (ja) 2006-06-06 2009-08-27 Mitsubishi Tanabe Pharma Corp ２−シアノピロリジン誘導体
FR2901792A1 (fr) 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
US20070287674A1 (en) 2006-06-08 2007-12-13 Hej Research Institute Of Chemistry New treatment of diabetes mellitus
TW200808695A (en) 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
EP2029540B1 (en) 2006-06-08 2010-08-04 Amgen Inc. Benzamide derivatives and uses related thereto
AU2007255366B2 (en) 2006-06-09 2013-07-18 Synact Pharma Aps Phenyl pyrrole aminoguanidine derivatives
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
WO2007146761A2 (en) 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
WO2008035359A2 (en) 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
CA2655282A1 (en) 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted piperidine carboxamides
US20100048714A1 (en) 2006-06-19 2010-02-25 University Of Utah Research Foundation Methods and Compositions Related to Inhibition of Ceramide Synthesis
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US20100234439A1 (en) 2006-06-20 2010-09-16 Leifeng Cheng Therapeutic agents
CN101472897A (zh) 2006-06-20 2009-07-01 阿斯利康(瑞典)有限公司 治疗剂
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008001160A1 (en) 2006-06-23 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
WO2007150026A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008002575A1 (en) 2006-06-26 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
TW200815418A (en) 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
CN101096363B (zh) 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
TW200815417A (en) 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
SI2040713T1 (sl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
TW200811158A (en) 2006-06-27 2008-03-01 Sanofi Aventis Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
EP2743268A3 (en) 2006-06-27 2014-10-08 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
US20080004281A1 (en) 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8115017B2 (en) 2006-06-29 2012-02-14 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
US20080004325A1 (en) 2006-06-29 2008-01-03 Wyeth PTP1B inhibitors
EP2035372A1 (en) 2006-06-29 2009-03-18 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
CN101479249B (zh) 2006-06-29 2012-10-10 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
CN101511775A (zh) 2006-06-29 2009-08-19 詹森药业有限公司 丁基和丁炔基苄基胺化合物
AU2007265242A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
US20080045507A1 (en) 2006-06-29 2008-02-21 Allison Brett D Substituted benzamide modulators of the histamine h3 receptor
AU2007265240A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted aminomethyl benzamide compounds
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
JP4959794B2 (ja) 2006-07-05 2012-06-27 エフ．ホフマン−ラ ロシュ アーゲー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型（１１β−ＨＳＤ１）の阻害剤としてのアルキルピリダジン誘導体
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
DE102006031176A1 (de) 2006-07-06 2008-01-10 Bayer Healthcare Ag Substituierte Benzoxepino-isoxazole und ihre Verwendung
JP5194588B2 (ja) 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7803799B2 (en) 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101100458A (zh) 2006-07-07 2008-01-09 上海艾力斯医药科技有限公司 具有PPARγ激动剂活性的双苯并咪唑衍生物及其应用
FR2903404B1 (fr) 2006-07-10 2008-08-22 Servier Lab Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8134004B2 (en) 2006-07-11 2012-03-13 Pfizer Inc. Substituted N-bicyclicalkyl bicycliccarboxyamide compounds
US7297710B1 (en) 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
EP2043744A2 (en) 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
US8048908B2 (en) 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
EP1878721A1 (en) 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
US20100010530A1 (en) 2006-07-14 2010-01-14 Ams Research Corporation Balloon Dilation for Implantable Prosthesis
CA2657787A1 (en) 2006-07-14 2008-01-17 Merck And Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
DE602007008434D1 (de) 2006-07-14 2010-09-23 Merck Sharp & Dohme Rezeptoren
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
JP5372318B2 (ja) 2006-07-14 2013-12-18 パナソニック株式会社 電気化学キャパシタの製造方法
JP2009543823A (ja) 2006-07-17 2009-12-10 ノバルティス アクチエンゲゼルシャフト 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
KR101149274B1 (ko) 2006-07-20 2012-05-29 노파르티스 아게 Ｃετρ 억제제로서의 아미노-피페리딘 유도체
GB2454615A (en) 2006-07-21 2009-05-13 Lupin Ltd Antidiabetic azabicyclo (3.1.0) hexan compounds
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
JP2008031064A (ja) 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008016730A2 (en) 2006-08-02 2008-02-07 Targeted Molecular Diagnostics, Llc Compositions and methods for reducing cellular fat
CA2658797A1 (en) 2006-08-02 2008-02-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
WO2008016175A1 (fr) 2006-08-03 2008-02-07 Nippon Chemiphar Co., Ltd. Agent activant de récepteur activé par les proliférateurs des peroxysomes
WO2008016123A1 (fr) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
JP5270545B2 (ja) 2006-08-03 2013-08-21 タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ フラッシングのないナイアシン類似体およびそれらの使用法
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
WO2008019309A1 (en) 2006-08-04 2008-02-14 Metabasis Therapeutics, Inc. Novel inhibitors of fructose 1,6-bisphosphatase
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
KR100826108B1 (ko) 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
SG176477A1 (en) 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
EP1887006A1 (en) 2006-08-07 2008-02-13 Krka Polymorphic forms of rosiglitazone base
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2008017852A1 (en) 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators
BRPI0715893A2 (pt) 2006-08-15 2013-09-17 Actelion Pharmaceuticals Ltd composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
JP2009256208A (ja) 2006-08-17 2009-11-05 Dainippon Sumitomo Pharma Co Ltd フタリド誘導体またはその薬学的に許容される塩
WO2008021625A2 (en) 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2008024284A2 (en) 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators
ATE530540T1 (de) 2006-08-23 2011-11-15 Pfizer Prod Inc Pyrimidonverbindungen als gsk-3-inhibitoren
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
CN101563349A (zh) 2006-08-23 2009-10-21 神经能质公司 经卤烷基取代的嘧啶酮衍生物
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008024497A2 (en) 2006-08-25 2008-02-28 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
ATE458740T1 (de) 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
WO2008029217A2 (en) 2006-08-29 2008-03-13 Orchid Research Laboratories Limited Dipeptidyl peptidase iv inhibitors
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
JP5187901B2 (ja) 2006-08-30 2013-04-24 塩野義製薬株式会社 ヒドラジンアミド誘導体
JP5207382B2 (ja) 2006-08-30 2013-06-12 塩野義製薬株式会社 ウレア誘導体
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
CA2660699A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2008027584A2 (en) 2006-09-01 2008-03-06 Vertex Pharmaceuticals Incorporated 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
US7470697B2 (en) 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
WO2008028188A2 (en) 2006-09-01 2008-03-06 The Ticket Reserve Demand aggregation for future items contingent upon threshold demand
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2008063256A (ja) 2006-09-06 2008-03-21 Astellas Pharma Inc β‐アミノ酸誘導体
WO2008031032A2 (en) 2006-09-07 2008-03-13 Transition Therapeutics Inc. Compounds for and methods of treating insulin resistance and inflammation
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
WO2008028662A1 (en) 2006-09-07 2008-03-13 Santhera Pharmaceuticals (Schweiz) Ag N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
JP2010502711A (ja) 2006-09-08 2010-01-28 ザ スクリプス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼの置換オキサゾールケトンモジュレーター
EP2064199A1 (en) 2006-09-08 2009-06-03 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
JP2010503654A (ja) 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
KR100886466B1 (ko) 2006-09-12 2009-03-04 (주)한국씨엔에스팜 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
AR062760A1 (es) 2006-09-13 2008-12-03 Takeda Pharmaceutical Administracion de inhibidores de dipeptidilpetidasa
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
WO2008033934A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US20100016274A1 (en) 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
CN101528227A (zh) 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
MX2009002924A (es) 2006-09-15 2009-05-28 Schering Corp Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
CN101583612A (zh) 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
ES2349066T3 (es) 2006-09-15 2010-12-22 Pfizer Inc. Compuestos de piridilmetilbiciclocarboxamida sustituida.
MX2009003125A (es) 2006-09-20 2009-05-28 Lilly Co Eli Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
WO2008035356A2 (en) 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2008036021A1 (en) 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
WO2008036022A1 (en) 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
CA2664245A1 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
EP2097410A4 (en) 2006-09-29 2009-11-25 Green Cross Corp HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
JP2010504957A (ja) 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
KR101077309B1 (ko) 2006-09-29 2011-10-26 에프. 호프만-라 로슈 아게 설폰아미드 유도체
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
WO2008044656A1 (fr) 2006-10-06 2008-04-17 Taisho Pharmaceutical Co., Ltd. Dérivé d'imidazolidinone
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
WO2008040974A1 (en) 2006-10-07 2008-04-10 Peakdale Molecular Limited Indoles for use as dpp-iv inhibitors
US8022061B2 (en) 2006-10-10 2011-09-20 Amgen Inc. N-aryl pyrazole compounds, compositions, and methods for their use
US20110039893A1 (en) 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
US20080139455A1 (en) 2006-10-12 2008-06-12 Forbes Medi-Tech (Research), Inc. Compounds and methods of treating metabolic syndrome and inflammation
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
WO2008044111A1 (en) 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
US20080107725A1 (en) 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
JPWO2008044762A1 (ja) 2006-10-13 2010-02-18 中外製薬株式会社 チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用
DE102006048728A1 (de) 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
CA2849697A1 (en) 2006-10-16 2008-04-24 Alexandros Eleftheriadis Systems and methods for signaling and performing temporal level switching in scalable video coding
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CA2666489C (en) 2006-10-19 2012-10-02 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
TW200825072A (en) 2006-10-20 2008-06-16 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
EP2099450A4 (en) 2006-10-20 2011-01-26 Merck Sharp & Dohme NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF TREATMENT
JP2010507587A (ja) 2006-10-20 2010-03-11 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
ES2368460T3 (es) 2006-10-23 2011-11-17 Pfizer Inc. Compuestos de fenilmetil biciclocarboxiamida sustituidos.
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
KR100812538B1 (ko) 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
US20080103201A1 (en) 2006-10-26 2008-05-01 Wijayabandara Mirihanage Don J Novel alpha-Glucosidase inhibitor from Tabernaemontana dichotoma
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
EP2079467B1 (en) 2006-10-31 2015-11-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN101535238A (zh) 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008057856A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
ATE550337T1 (de) 2006-11-01 2012-04-15 Bristol Myers Squibb Co Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
US8263587B2 (en) 2006-11-02 2012-09-11 Piramal Healthcare Limited Benzoxazepine compounds, their preparation and use
WO2008057336A2 (en) 2006-11-02 2008-05-15 Merck & Co., Inc. Heterocyclyl-substituted anti-hypercholesterolemic compounds
EP1918281A1 (en) 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
CN101535249A (zh) 2006-11-02 2009-09-16 塞诺菲-安万特德国有限公司 具有改善的药理性质的新的哌嗪-1-磺酸取代的二苯基氮杂环丁酮
EP2086965B1 (en) 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
EP1918285A1 (en) 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
WO2008056377A2 (en) 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
EP2079753A1 (en) 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1921080B1 (en) 2006-11-07 2009-08-05 Sanofi-Aventis Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives
JP2010043001A (ja) 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
NZ598778A (en) 2006-11-09 2013-09-27 Boehringer Ingelheim Int Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
EP1921072A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
GB0622569D0 (en) 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
DE102006053636B4 (de) 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
ATE493992T1 (de) 2006-11-14 2011-01-15 Sanofi Aventis Deutschland Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102006053635B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053637B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2669221A1 (en) 2006-11-15 2008-05-22 Novartis Ag Heterocyclic derivatives as cetp inhibitors
KR20090078352A (ko) 2006-11-15 2009-07-17 노파르티스 아게 유기 화합물
EP2111865B1 (en) 2006-11-17 2019-10-02 National University Corporation Kagawa University Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm
CA2669915C (en) 2006-11-17 2012-02-07 Pfizer Inc. Substituted bicyclocarboxyamide compounds
CN101595109B (zh) 2006-11-20 2012-09-05 百时美施贵宝公司 作为二肽基肽酶ⅳ抑制剂的7，8-二氢-1，6-二氮杂萘-5（6h）-酮和相关二环化合物及方法
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
AU2007334519A1 (en) 2006-12-14 2008-06-26 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment

Also Published As

Publication number Publication date
DOP2010000059A (es) 2010-02-28
UY31288A1 (es) 2009-03-31
AR068059A1 (es) 2009-11-04
CL2008002414A1 (es) 2009-07-17
CN101784536A (zh) 2010-07-21
EP2188273B1 (de) 2014-10-22
WO2009021740A3 (de) 2009-05-14
WO2009021740A2 (de) 2009-02-19
CR11235A (es) 2010-05-19
ZA201000520B (en) 2010-10-27
TW200930711A (en) 2009-07-16
JP2010535827A (ja) 2010-11-25
KR20100063700A (ko) 2010-06-11
MX2010001503A (es) 2010-03-10
CA2695955A1 (en) 2009-02-19
AU2008286316A1 (en) 2009-02-19
BRPI0815206A2 (pt) 2015-03-31
TN2010000075A1 (en) 2011-09-26
US20100249097A1 (en) 2010-09-30
PA8793401A1 (es) 2009-03-31
CO6331303A2 (es) 2011-10-20
US8609731B2 (en) 2013-12-17
EP2025674A1 (de) 2009-02-18
SV2010003480A (es) 2010-05-26
RU2010109416A (ru) 2011-09-20
NI201000024A (es) 2010-07-29
PE20090986A1 (es) 2009-08-14
EP2188273A2 (de) 2010-05-26
US20140088077A1 (en) 2014-03-27
MA31611B1 (fr) 2010-08-02

Similar Documents

Publication Publication Date Title
ECSP109967A (es) Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparación y uso de los mismos como medicamentos
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos
DOP2007000024A (es) Composiciones herbicidas concentradas y estables
CL2008002794A1 (es) Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero.
CR8581A (es) 5,6 dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
DOP2011000171A (es) Compuestos organico
CL2008003083A1 (es) Uso de un beta bloqueador seleccionado de un beta bloqueador no selectivo y/o un beta bloqueador selectivo beta-1 para preparar un medicamento util para el tratamiento de los hemangiomas.
CO6420333A2 (es) Herbicidas novedosos
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
AR078113A1 (es) Composiciones agroquimicas que contienen alquil polipropilenglicolpolietilenglicol
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
PA8660601A1 (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
ATE485261T1 (de) Salicylsäurederivate
AR072840A1 (es) Uso de reguladores del crecimiento de plantas para reducir el amarillamiento de las hojas de planta relacionado con el acido abscisico
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
BR112012021108A2 (pt) composições biocidas, e, uso de valerolactona e/ou de seus derivados de amida
BR112012028559A2 (pt) composições biocidas, e, uso de ésteres de oligoglicerol alcoxilados
UY28911A1 (es) Profármacos de esteroides con acción androgénica
DK1869032T3 (da) Pyrimidindervater til anvendelse som anticancermidler
BR112012011544A2 (pt) composição biocidas compreendendo carbamatos
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
AR060155A1 (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos